Avalo Therapeutics(AVTX)

Focus: Avalo Therapeutics is a public biotech company focused on small-molecule therapeutics for neuropsychiatric and other disorders, currently in early-to-mid stage clinical development with minimal revenue.

Psychiatry

Profile data last refreshed 1h ago · AI intelligence enriched 2mo ago

Funding Stage

PUBLIC

Open Jobs

8+8 this month

Growing — net +8 jobs in 30d

9 jobs added vs 1 removed. Steady team buildout.

Should You Work at Avalo Therapeutics?

AI assessment

Avalo offers high scientific impact and clinical catalyst upside for risk-tolerant biotech professionals, but limited hiring activity and preclinical financial runway suggest this is suitable only for those seeking early-stage exposure without near-term commercial scale.

Why Work Here

Substantial cash position of $135M (FY2025) provides runway for clinical programs in psychiatry and ADHD, a high-unmet-need market.

Data completeness

5/9 — Partial

Company HealthStrong

Pipeline

Early-stage

13 total

LOE Risk

Protected

No near-term cliffs

Hiring

Growing

Jobs increasing

Pipeline & Clinical Trials

A Non-interventional Study to Identify Children and Adolescents With ADHD and With or Without mGLuR

Attention Deficit Hyperactivity Disorder

N/A

Clinical Trials (1)

NCT03233867A Non-interventional Study to Identify Children and Adolescents With ADHD and With or Without mGLuR Mutations

N/A

Help build intelligence for Avalo Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Diverse pipeline of 12 programs across Phase 1-3 with NFC-1 in Phase 2/3 for ADHD and CERC-301 in Phase 2 for major depressive disorder offering multiple clinical catalysts.

Early-stage company profile enables direct impact on drug development and potential rapid career progression in clinical, regulatory, and scientific roles.

Watch Out For

Minimal revenue ($441K FY2025) and recurring large net losses ($35.1M FY2025) indicate the company is entirely R&D-dependent with no commercial infrastructure.
Zero active job openings and lack of hiring data suggest limited near-term expansion plans or team building, reducing external hiring opportunities.
Extreme R&D intensity (5541%) and absence of approved products create significant execution risk; failure of lead programs could jeopardize financial stability.

Generated by Claude from Avalo Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

A Noninterventional Genotype/Phenotype Study of mGluR Mutations in Children and Adolescents With ADH

Attention Deficit Disorder With Hyperactivity

N/A

Clinical Trials (1)

NCT02811211A Noninterventional Genotype/Phenotype Study of mGluR Mutations in Children and Adolescents With ADHD

N/A

MDGN-002

Crohn's Disease

Phase 1

Clinical Trials (1)

NCT03169894Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease or Ulcerative Colitis

Phase 1

AEVI-007

Multiple Myeloma

Phase 1

Clinical Trials (1)

NCT04671251Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma

Phase 1

CERC-006

Lymphatic Malformation

Phase 1

Clinical Trials (1)

NCT04994002A Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Study of CERC-006 in Adults With Complex Lymphatic Malformations

Phase 1

AVTX-002

Non-Eosinophilic Asthma

Phase 2

Clinical Trials (1)

NCT05288504A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma.

Phase 2

CERC-002

COVID-19 Pneumonia

Phase 2

Clinical Trials (1)

NCT04412057Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury

Phase 2

FP01

Acute Cough

Phase 2

Clinical Trials (3)

NCT01597349Antitussive Effects of FP01 Lozenges in Subjects With Cough Due to Upper Respiratory Tract Infection

Phase 2

NCT01703923An Exploratory Study of FP01 Lozenges in Subjects With Chronic Refractory Cough

Phase 2

NCT01579526A Single Dose Study to Determine the Safety and Pharmacokinetics of FP01 Lozenges in Healthy Volunteers

Phase 1

AVTX-009

Hidradenitis Suppurativa

Phase 2

Clinical Trials (1)

NCT06603077A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa

Phase 2

CERC-301

Major Depressive Disorder

Phase 2

Clinical Trials (2)

NCT02459236A Study of Intermittent Doses of CERC-301 in MDD

Phase 2

NCT01941043A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Study of CERC-301 in the Adjunctive Treatment of Subjects With Severe Depression and Recent Active Suicidal Ideation Despite Antidepressant Treatment

Phase 2

MDGN201 TARGTEPO

Anemia of End Stage Renal Disease

Phase 2

Clinical Trials (1)

NCT02468414TARGTEPO Treatment for Anemia in PD US Trial

Phase 2

AEVI-001

Attention Deficit Hyperactivity Disorder

Phase 2

Clinical Trials (2)

NCT03609619PART B: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and Without mGluR Mutations

Phase 2

NCT03265119PART A: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and With mGluR Mutations

Phase 2

NFC-1

Attention Deficit Hyperactivity Disorder

Phase 2/3

Clinical Trials (4)

NCT02777931Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHD

Phase 2/3

NCT03006367Pharmacokinetic and Tolerability Study of NFC-1 in Subjects Aged 6-17 Years With ADHD

Phase 1

NCT02895906Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric Conditions

Phase 1

+1 more

Interview Prep Quick Facts

Portfolio: 20 clinical trials

Top TAs: Respiratory, Dermatology, Hematology

Publications: 2 in PubMed

SEC Filings: 2 available

Open Roles: 8 active jobs

Therapeutic Area Focus

3 pipeline

1 pipeline

1 pipeline

1 pipeline

1 pipeline

Financials (FY2025)

Revenue

$441K77%

R&D Spend

$24M(5541%)77%

Net Income

-$35M

Hiring Trend

Actively Hiring

Open Roles

Added

-1

Filled/Removed

Based on last 4 crawl cycles

Research Publications(2)

Recent peer-reviewed publications with author affiliations at this company

Realigning the LIGHT signaling network to control dysregulated inflammation.

The Journal of experimental medicine

2022

PMID:35604387

Randomized, double-blind, controlled trial of human anti-LIGHT monoclonal antibody in COVID-19 acute respiratory distress syndrome.

The Journal of clinical investigation

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Avalo Therapeutics(AVTX)

Should You Work at Avalo Therapeutics?

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Recent News · Avalo Therapeutics(10)

Open Jobs (8)

Sr. Manager/ Associate Director, Biostatistics

Head of Global Marketing & Launch Lead, Dermatology

Sr. Manager/ Associate Director, Statistical Programming

Sr. Manager/ Associate Director, Data Management

General Application

Medical Director/Sr. Medical Director, Clinical Development

Sr. Manager, Quality Assurance

Clinical Trial Manager

Financials (FY2025)

Hiring Trend

Research Publications(2)